NEW ORLEANS -- Microaxial flow pump circulatory support with the Impella device during percutaneous coronary intervention (PCI) didn't help outcomes for complex patients not in cardiogenic shock, two randomized trials at the American College of Cardiology (ACC) annual meeting showed.
In an elective and largely stable but high-risk population in the CHIP-BCIS3 trial, Bayesian win ratio favored PCI ...
Impella device use during PCI did not improve outcomes for complex patients who were not in cardiogenic shock, according to two randomized trials presented at the ACC annual meeting. The CHIP-BCIS3 trial found that planned use of a microaxial flow pump during PCI had worse all-cause and cardiovascular mortality compared to PCI without planned circulatory support. The STEMI Door to Unload (DTU) trial showed no impact on infarct size or clinical outcomes, but all-cause and cardiovascular mortality...